# 506U78 in Treating Patients With Refractory Hematologic Cancer

> **NCT00002970** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 148 (actual)

## Conditions studied

- Recurrent Childhood Acute Lymphoblastic Leukemia
- Recurrent Childhood Lymphoblastic Lymphoma
- T-cell Childhood Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** nelarabine
- **DRUG:** methotrexate
- **DRUG:** cytarabine
- **DRUG:** therapeutic hydrocortisone

## Key facts

- **NCT ID:** NCT00002970
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-06
- **Primary completion:** 2005-01
- **Final completion:** —
- **Target enrollment:** 148 (ACTUAL)
- **Last updated:** 2013-07-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002970, "506U78 in Treating Patients With Refractory Hematologic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00002970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*